DGAP-News: MorphoSys Provides Update on Impact of COVID-19 on Business Operations and Precautionary Measures
DGAP-News: MorphoSys AG
/ Key word(s): Miscellaneous
Planegg/Munich, Germany, April 6, 2020 MorphoSys Provides Update on Impact of COVID-19 on Business Operations and Precautionary Measures MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) provided an update on its business and the measures the Company is taking to mitigate the impact of the rapidly evolving global COVID-19 pandemic on its employees, patients and the broader community. "The well-being of our employees and patients is our top priority," said Jean-Paul Kress, M.D., CEO and Chairman of the MorphoSys Management Board. "In this unprecedented crisis, we are committed to taking every necessary precaution to help reduce the spread of the virus and to break the cycle of infection. While we are working closely with the sites and our investigators to mitigate the impact of the COVID-19 pandemic on our clinical studies and to continue delivering the medicines our patients desperately need, we are putting their safety and that of the site personnel first. We are closely monitoring the COVID-19 situation and are continuously evolving our mitigation efforts to support the long-term value of our business." Impact on Employees and Business Operations: MorphoSys has activated its business continuity plans to minimize business disruption and ensure the well-being of its staff. A number of actions were implemented, aiming at slowing the spread of COVID-19 and to protect the health and safety of our employees and their families, including a mandatory work-from-home policy for those able to perform their jobs from home, flexible work schedules, restrictions on in-person meetings, visitor access to MorphoSys sites and business travel. Clinical Trials: MorphoSys is conducting a number of clinical studies with its investigational medicines, and is closely monitoring each program individually and the overall situation. The Company is making adjustments where necessary, responding to regulatory, institutional, and government guidance and policies related to COVID-19. The top priority is to ensure the safety of all participants in its clinical programs and the integrity of the studies in which they participate. An increasing number of clinical trial sites are restricting site and patient visits to protect both site staff and patients from possible COVID-19 exposure. Consequently, MorphoSys is continuously monitoring the situation and deciding how to proceed on a "study-by-study" and "country-by-country" basis to ensure patient safety and data integrity. - Accordingly, enrollment/screening of patients in the M-PLACE study with MOR202 is temporarily paused. This could lead to delays in previously communicated timelines. - Enrollment of patients will continue in studies with the potential for significant benefit in life-threatening indications. - Already enrolled patients will continue to receive study drug. The Company remains committed to maintaining its development plans but acknowledges the potential impact on clinical studies given the rapidly evolving global environment. MorphoSys maintains previously communicated guidance on its 2020 corporate milestones. However, the situation is highly dynamic and it is not possible to reliably predict or quantify the potential impact on ongoing and planned clinical studies and business operations. MorphoSys will continue to monitor and evaluate the situation and will provide updates on its website, and in connection with its upcoming quarterly reportings. About MorphoSys MorphoSys forward looking statements
Additional features: Document: https://eqs-cockpit.com/c/fncls.ssp?u=OVEKCQOWKX Document title: Media release
06.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | [email protected] |
Internet: | www.morphosys.com |
ISIN: | DE0006632003 |
WKN: | 663200 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 1016831 |
End of News | DGAP News Service |
|
1016831 06.04.2020
MorphoSys AG Stock
MorphoSys AG is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
However, we have a potential of -4.06% for MorphoSys AG as the target price of 65 € is below the current price of 67.75 €.